Circio Holding ASA (OSL:CRNA)

Market Cap	163.73M +186.5%
Revenue (ttm)	n/a
Net Income	-6.60M
EPS	-0.11
Shares Out	143.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109,591
Average Volume	2,366,537
Open	1.158
Previous Close	1.140
Day's Range	1.120 - 1.158
52-Week Range	0.480 - 1.852
Beta	1.48
RSI	51.39
Earnings Date	Apr 9, 2026

About Circio Holding ASA

Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a collaboration with Certest Biotec, S.L. for formulation of circVec. The company was formerly known as Targovax ASA and changed its name to Circio Holdi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 9
• Stock Exchange: Oslo Børs
• Ticker Symbol: CRNA